open access

Vol 12, No 3 (2017)
Case Reports
Published online: 2017-06-30
Get Citation

Idarucizumab in clinical practice. Gastrointestinal bleeding that is life-threatening in an 83-year-old patient

Anna Szpotowicz, Iwona Gorczyca-Michta, Małgorzata Krzciuk, Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2017.0059
·
Folia Cardiologica 2017;12(3):303-305.

open access

Vol 12, No 3 (2017)
Case Reports
Published online: 2017-06-30

Abstract

Idarucizumab is a specifi c agent that reverts the effects of dabigatran while not affecting the activity of other anticoagulants. It selectively binds dabigatran and its metabolites thus neutralizing their anticoagulant activity. Idarucizumab is the fi rst agent to revert the effects of non-vitamin K antagonist oral anticoagulants.

Abstract

Idarucizumab is a specifi c agent that reverts the effects of dabigatran while not affecting the activity of other anticoagulants. It selectively binds dabigatran and its metabolites thus neutralizing their anticoagulant activity. Idarucizumab is the fi rst agent to revert the effects of non-vitamin K antagonist oral anticoagulants.

Get Citation

Keywords

idarucizumab, dabigatran, NOAC, przeciwciało monoklonalne

About this article
Title

Idarucizumab in clinical practice. Gastrointestinal bleeding that is life-threatening in an 83-year-old patient

Journal

Folia Cardiologica

Issue

Vol 12, No 3 (2017)

Pages

303-305

Published online

2017-06-30

DOI

10.5603/FC.2017.0059

Bibliographic record

Folia Cardiologica 2017;12(3):303-305.

Keywords

idarucizumab
dabigatran
NOAC
przeciwciało monoklonalne

Authors

Anna Szpotowicz
Iwona Gorczyca-Michta
Małgorzata Krzciuk
Beata Wożakowska-Kapłon

References (7)
  1. Stępińska J, Wożakowaka-Kapłon B, Pruszczyk P, et al. [Non-vitamin K oral antagonist no more new!]. Kardiol Pol. 2014; 72(9): 854–855.
  2. Huisman MV, Lip GYH, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012; 107(5): 838–847.
  3. Lauffenburger JC, Rhoney DH, Farley JF, et al. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy. 2015; 35(6): 560–568.
  4. Pollack CV. Idarucizumab for dabigatran reversal: updated results of the RE-VERSE AD study. Presented at 2016 American Heart Association Scientific Sessions 2016. New Orleans, Louisiana, 2016.
  5. Styczeń A, Falkiewicz M, Karaś-Głodek M, et al. Eteksylan dabigatranu a idarucizumab. Folia Cardiol. 2016; 11(4): 284–292.
  6. Wesołowska K, Woronowicz-Chróściel A, Kluk M, et al. Idarucizumab — nowy poziom terapii przeciwkrzepliwe. Opis leczenia powikłań krwotocznych u 93-letniej chorej. Folia Cardiol. 2016; 11: 554–556.
  7. Tomaszuk-Kazberuk A, Łopatowska P, Młodawska E, et al. Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm. Pol Arch Intern Med. 2017; 127(1): 68–70.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl